monoclon
antibodi
therapi
game
changer
cancer
therapi
includ
treatment
lymphoma
human
epiderm
growth
factor
receptor
breast
cancer
howev
approach
limit
includ
slow
develop
timelin
limit
modif
option
short
halflif
molecul
requir
frequent
repeat
administr
limit
contribut
high
cost
develop
deploy
import
tool
repres
challeng
develop
combin
approach
import
recent
advanc
field
monoclon
technolog
bispecif
cell
engag
bite
combin
specif
mab
cytotox
potenti
cell
bite
shown
promis
result
leukemia
clinic
trial
howev
therapi
limit
applic
requir
continu
intraven
infus
week
manufactur
limit
longerliv
simpler
reproduc
product
method
antibodybas
product
would
import
cancer
immunotherapi
plasmid
dnaencod
antibodi
dmab
recent
explor
treat
infecti
diseas
cancer
approach
present
uniqu
advantag
convent
protein
antibodi
encod
viral
vector
vivo
deliveri
includ
simplic
engin
deliveri
short
develop
time
product
longer
vivo
express
without
gene
integr
previou
attempt
deliv
dnaencod
antibodi
result
function
low
level
express
howev
novel
design
deliveri
formul
improv
permit
higher
longer
express
manuscript
describ
develop
highexpress
dmab
target
modif
new
molecul
develop
potenti
novel
bite
target
studi
molecul
therapeut
model
treatment
ovarian
breast
cancer
show
specif
antibodi
therapi
includ
mab
bispecif
cell
engag
bite
import
new
tool
cancer
immunotherapi
howev
approach
slow
develop
may
limit
product
thu
restrict
patient
access
treatment
bite
exhibit
particularli
short
halflif
difficult
product
develop
approach
allow
simplifi
develop
deliveri
vivo
product
would
import
advanc
describ
develop
design
synthet
dna
plasmid
optim
permit
high
express
antibodi
deliv
anim
adapt
electropor
effici
express
vitro
vivo
reach
level
mous
sera
mechanist
block
signal
induc
antibodydepend
cytotox
delay
tumor
progress
ovarian
breast
cancer
model
next
use
singlechain
variabl
fragment
portion
engin
dnaencod
bite
dbite
express
vivo
approxim
month
singl
administr
highli
cytolyt
delay
cancer
progress
mice
studi
illustr
approach
gener
dbite
vivo
repres
promis
immunotherapi
tumor
includ
ovarian
potenti
cancer
construct
express
high
level
vitro
vivo
approxim
month
bind
induc
signal
blockad
antibodydepend
cellular
cytotox
dnaencod
bite
effect
induc
cell
cytotox
tumor
cell
result
high
proport
tumor
regress
potenti
novel
synthet
dna
approach
repres
new
tool
studi
immunotherapi
cancer
design
express
develop
encod
codon
rnaoptim
sequenc
heavi
light
chain
pertuzumab
modifi
pvax
plasmid
express
vector
figur
test
antibodi
express
vitro
transfect
cell
synthet
dna
irrelev
dnaencod
protein
collect
supernat
perform
western
blot
analysi
hour
later
easili
identifi
band
correspond
heavi
light
antibodi
chain
supernat
irrelev
protein
control
figur
express
valid
use
rd
cell
supplement
figur
supplement
materi
avail
onlin
articl
http
confirm
vitro
express
studi
vivo
express
inject
empti
vector
follow
adapt
electropor
tibiali
anterior
muscl
mice
identifi
presenc
human
igg
sera
mice
control
figur
level
express
high
mous
sera
figur
express
last
month
figur
next
examin
dnaencod
human
igg
would
bind
coat
plate
protein
incub
sera
mice
control
sera
mous
sera
bound
dosedepend
manner
figur
confirm
bind
protein
present
cell
surfac
overexpress
murin
cell
line
bound
flow
cytometri
ectop
express
figur
express
human
ovarian
cancer
cell
line
overexpress
histolog
score
approxim
ovarian
cancer
determin
whether
also
express
ovarian
cancer
cell
line
perform
flow
cytometri
use
commerci
antibodi
figur
valid
bind
flow
cytometri
cell
figur
valid
vivo
express
potenti
target
ovarian
cancer
cell
line
use
gener
tumor
mice
perform
immunofluoresc
frozen
tumor
section
found
posit
bind
use
sera
mice
control
sera
confirm
vivo
express
relev
bind
figur
mediat
signal
blockad
antibodydepend
cellular
cytotox
differ
mechan
attribut
antitumor
effect
anticanc
antibodi
pertuzumab
act
prevent
heterodimer
agonistmedi
signal
expect
prevent
agonist
heregulininduc
hrginduc
signal
cell
evidenc
decreas
akt
phosphoryl
compar
vehicl
control
figur
support
conserv
mechan
action
reduct
pakt
stronger
presenc
hrg
absenc
support
action
dimer
inhibit
never
complet
activ
one
multipl
mechan
induc
activ
akt
pathway
anoth
mechan
mab
antitumor
activ
antibodydepend
cellular
cytotox
adcc
studi
adcc
potenti
incub
cell
without
peripher
blood
mononuclear
cell
pbmc
presenc
sera
empti
vectortr
mice
sera
effect
kill
ovarian
cancer
cell
presenc
pbmc
similar
commerci
avail
absenc
kill
observ
control
sera
condit
figur
supplement
figur
line
supplement
figur
similarli
show
antibodydepend
phagocytosi
activ
supplement
figur
delay
cancer
progress
vivo
determin
antitumor
effect
vivo
challeng
nude
mice
ovarian
cancer
cell
line
nude
mice
cell
present
enhanc
nk
macrophag
activ
splenocyt
lyse
vitro
presenc
supplement
figur
deliv
empti
vector
muscl
electropor
tumor
reach
averag
mm
anim
demonstr
signific
delay
tumor
growth
result
improv
surviv
figur
level
peak
week
dmab
inject
level
around
sustain
level
around
month
end
experi
figur
valid
antitumor
effect
immunocompet
host
gener
tumor
use
murin
breast
cancer
cell
line
caveat
spontan
immunogen
mice
engin
cell
line
express
similar
level
figur
treat
mice
empti
vector
day
tumor
challeng
also
delay
tumor
progress
aggress
model
breast
cancer
figur
upon
studi
kinet
note
decreas
antibodi
express
almost
day
investig
phenomenon
look
induct
antibodi
human
construct
express
mice
observ
develop
antibodi
sera
treatment
supplement
figur
may
contribut
declin
time
gener
express
cytotox
bite
bind
antibodi
fragment
singlechain
variabl
fragment
scfv
develop
engag
target
tumor
antigen
engag
immun
system
bind
drive
cell
activ
tumor
reason
optim
engin
vivo
express
would
also
excel
start
point
engin
accordingli
fuse
scfv
scfv
optim
sequenc
encod
modifi
figur
effici
express
vivo
upon
inject
cellectra
inovio
electropor
mous
tibiali
anterior
muscl
figur
new
retain
bind
bound
supplement
figur
b
importantli
although
stimul
provid
report
capabl
kill
cell
nt
observ
increas
proport
apoptosi
differ
cell
number
cocultur
cell
compar
control
presenc
cell
supplement
figur
c
determin
function
express
vivo
cultur
sera
mice
inject
empti
vector
ovarian
cancer
cell
cell
sera
mice
treatment
show
cell
activ
supplement
figur
eg
effici
dosedepend
cytotox
cell
cytotox
found
upon
incub
sera
empti
vectortr
mice
observ
absenc
cell
figur
supplement
figur
incub
cell
ratio
sera
treat
mice
show
dbite
exhibit
potent
activ
approxim
month
figur
observ
gener
antibodi
could
part
respons
circul
level
time
supplement
figur
determin
dbite
antitumor
activ
vivo
challeng
nsg
mice
treat
mice
singl
administr
empti
vector
day
tumor
implant
two
week
tumor
inocul
tumor
approxim
mm
inject
pbmc
intraperiton
mous
treatment
significantli
affect
tumor
progress
figur
tumor
regress
tumor
elimin
observ
tumor
tumor
impact
observ
control
group
figur
vivo
effect
observ
absenc
pbmc
supplement
figur
studi
describ
gener
therapeut
use
optim
synthet
dnaencod
mab
dmab
well
dbite
deliv
vivo
cancer
immunotherapi
adapt
electropor
dmab
seri
advantag
tradit
protein
antibodi
first
dna
stabler
protein
higher
stabil
simplifi
storag
ship
current
strict
cold
chain
requir
antibodi
requir
increas
therapeut
cost
limit
vivo
product
halflif
show
intramuscular
deliveri
design
antibodyencod
dna
plasmid
achiev
stabl
plasma
antibodi
concentr
sever
month
limit
requir
multipl
administr
simplifi
treatment
strategi
well
provid
improv
express
profil
despit
high
antitumor
activ
bite
therapi
advanc
slowli
new
tool
limit
due
manufactur
problem
halflif
approxim
hour
short
halflif
impos
bite
therapi
administ
continu
intraven
infus
week
per
cycl
recent
experi
intraven
deliv
rna
express
bite
show
vivo
activ
day
deliv
simpl
inject
last
millisecond
express
vivo
approxim
month
result
sustain
dramat
antitumor
activ
synthet
dna
deliveri
bite
could
allevi
burden
gener
short
halflif
bite
therapi
provid
import
new
applic
tool
cancer
immunotherapi
report
focu
target
ovarian
cancer
larg
studi
identifi
overexpress
ovarian
tumor
pertuzumab
unlik
trastuzumab
requir
overexpress
tumor
cell
antitumor
activ
increas
potenti
popul
sensit
therapi
addit
pertuzumab
standard
chemotherapi
trastuzumab
breast
cancer
improv
progress
invas
diseasefre
surviv
breast
cancer
ovarian
cancer
pertuzumab
shown
trend
toward
increas
progressionfre
surviv
synthet
dna
platform
product
shown
would
allow
administr
pertuzumab
dmab
well
dbite
administr
combin
dnaencod
checkpoint
inhibitor
combin
approach
advantag
potenti
higher
antitumor
effect
use
simplifi
therapeut
regim
would
favor
adher
treatment
studi
also
observ
despit
long
halfliv
antiantibodi
respons
influenc
dmab
dbite
level
time
antibodi
human
abl
reduc
antiantibodi
respons
human
therapi
report
dmab
engin
limit
respons
antidrug
antibodi
ada
expect
implement
way
prevent
antiantibodi
respons
contribut
posit
influenc
dmab
circul
level
futur
studi
data
blinatumomab
bite
approv
date
show
develop
neutral
ada
less
patient
treat
studi
demonstr
allow
sever
month
durabl
express
drive
antitumor
activ
engin
express
form
bite
allow
signific
degre
potenc
vivo
dmabengin
sequenc
start
point
develop
improv
bite
launch
dna
cassett
result
improv
halflif
extend
antitumor
activ
approach
appear
valuabl
addit
explor
tool
treatment
ovarian
well
potenti
cancer
addit
experiment
detail
found
supplement
materi
anim
cell
line
nuj
mice
purchas
jackson
laboratori
nsg
mice
purchas
wistar
institut
anim
facil
cell
provid
jr
conejogarcia
depart
immunolog
moffitt
cancer
center
tampa
florida
provid
r
zhang
wistar
institut
gener
tumor
inject
cell
flank
matrigel
corn
dilut
pb
describ
previous
rd
cell
purchas
atcc
human
primari
pbmc
cell
monocyt
provid
healthi
donor
human
immunolog
core
univers
pennsylvania
mice
treat
inject
dna
resuspend
water
tibiali
anterior
muscl
per
leg
iuml
hyaluronidas
milliporesigma
follow
minut
inject
electropor
cellectra
devic
inovio
design
engin
encod
codonoptim
sequenc
heavi
light
chain
mab
pertuzumab
antibodi
chain
posit
sequenc
separ
furin
cleavag
site
substitut
origin
leader
sequenc
ige
leader
sequenc
design
encod
codonoptim
scfv
follow
scfv
modifi
antihuman
antibodi
ad
ige
leader
sequenc
construct
subclon
modifi
pvax
express
vector
figur
figur
nonrepl
nonintegr
plasmid
design
effici
deliveri
dna
vaccin
mab
use
empti
modifi
pvax
plasmid
neg
control
statist
differ
mean
experiment
group
calcul
use
unpair
student
test
anova
categor
variabl
measur
repeat
measur
analyz
use
anova
error
bar
repres
sem
surviv
rate
compar
use
logrank
test
statist
analys
done
use
graphpad
prism
p
valu
less
consid
statist
signific
studi
approv
anim
experi
approv
institut
anim
care
use
committe
wistar
institut
protocol
